** Shares of drug developer ImmunityBio IBRX.O up 1.3% at $8.61 premarket

** Co says sales of its cancer therapy Anktiva surged in 2025, with net product revenue up 700% to $113 mln

** Anktiva is approved for bladder cancer, a disease where abnormal cell growth affects the urinary bladder

** Co says drug now approved in 33 countries; Saudi Arabia also cleared Anktiva for lung cancer in Jan, with launch expected within two months

** Shares down ~23% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))